Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Vital Farms Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Vital Farms Inc trades at $8.83 (market cap $400.98M). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 77.5× Vital Farms Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| GEHC | VITL | |
|---|---|---|
Market Cap | $31.07B | $400.98M |
Volume | 3,443,020 | 1,181,598 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $40.85 |
52-Week Low | $59.48 | $8.28 |
Enterprise Value | $39.53B | $487.99M |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 15 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Vital Farms (VITL) trades at $9.34, down 1.37% amid bearish technical signals and challenging fundamentals. The stock faces pressure from declining earnings, with Q1 2026 missing expectations and Q3 2026 expected at -$0.13 EPS. Despite a 56% analyst buy rating and $13.11 consensus target, recent news highlights strategic review discussions and pricing pressures in the egg market. Revenue remains flat at $766M for 2026 with net margins collapsing to near-zero, while cash flow trends show significant operational challenges.
The outlook remains cautious with near-term headwinds from industry oversupply and margin compression. Investment opportunity exists if strategic options materialize, but risks include sustained profitability challenges and competitive pressures. Current valuation metrics suggest potential upside if execution improves, but investors should monitor Q3 earnings and strategic developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
